Video

What to Expect When Going on a PARP Inhibitor for Ovarian Cancer

Author(s):

Ursula A. Matulonis, M.D.

Chemotherapy and PARP inhibitors may share some side effects, but there are some major differences between the two when it comes to treating ovarian cancer.

PARP inhibitors are different than most other ovarian cancer treatments because they are oral agents administered daily.

However, according to Ursula A. Matulonis, M.D., chief of the Division of Gynecologic Oncology at the Dana-Farber Cancer Institute, there are some unifying side effects between PARP inhibitors and traditional ovarian cancer treatments, such as chemotherapy. These include fatigue and gastrointestinal issues.

While, chemotherapy-induced side effects can be long-lasting, most associated with PARP inhibitors stop after about four to six weeks of treatment, she added.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Dr. Elizabeth K. Lee discusses the RAINFOL-01 clinical trial evaluating treatment with Rina-S in advanced ovarian cancer.
Melanoma is a key cancer type for developing and testing immunotherapies prior to broader clinical application across other malignancies.
Image of Dr. Kumar.
Photo of a woman with shoulder-length black hair wearing a blazer
Image of a woman wearing a headband and glasses
Image of man.
Image of doctor.
CURE spoke with Andy Guinigundo to discuss the role that biomarkers play for patients with breast cancer.
Related Content
CURE spoke with Dr. Michael K. Wong and Dr. Diwakar Davar about the use of ctDNA for patients with melanoma, and where the field may be headed.
April 11th 2025

What Role May ctDNA Have in Melanoma Management?

Dr. Michael K. Wong
CURE spoke with Dr. Michael K. Wong and Dr. Diwakar Davar about the use of ctDNA for patients with melanoma, and where the field may be headed.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
image of dr. Lillian Siu.
April 3rd 2025

Breaking Down Early Signs and Symptoms of Head and Neck Cancer

Dr Lillian Siu
April is Head and Neck Cancer Awareness Month, and it is important to be aware of early signs and symptoms of the disease, as well as when to seek care.
Shannon Miller smiling at a podium while delivering the keynote address at the 2023 Extraordinary Healer event | Image credit: © ATA-GIRL PHOTOGRAPHY
May 4th 2023

Olympian Shares Her Cancer Experience: ‘Give Yourself Grace’

Brielle Benyon
Olympic gymnast, Shannon Miller, sat down with CURE® to discuss her experience with a rare type of ovarian cancer, and how her competitive mindset helped her through.
Ovaries.
March 31st 2025

Relacorilant Plus Chemo Meets Primary Goal in Ovarian Cancer Trial

Spencer Feldman
The phase 3 trial showed relacorilant with chemotherapy improved progression-free and overall survival in platinum-resistant ovarian cancer.
Illustration of ovaries.
March 24th 2025

First Patient Dosed in Phase 3 Trial of IBI354 for Ovarian Cancer

Spencer Feldman
The first patient was dosed in a phase 3 trial of IBI354 for platinum-resistant ovarian cancer with HER2 expression.